Upon treatment with actinomycin D (Act D), CDKN1B mRNA degradation rates in UMUC3 (miR-190 inhibitor) cells were much lower than those in UMUC3 (LacZ) cells (Fig. 3c), revealing that miR-190 inhibition stabilizes CDKN1B mRNA in human BC cells. The gene discussed is CDKN1B; the disease is breast cancer.